SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.
3D Nasal Cast Model
For Admin
Translational Research
Business
A Leading Company in Nasal Drug Delivery
November 14, 2022
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced topline results from the STS101 SUMMIT Phase 3 efficacy trial for acute treatment of...
September 21, 2022
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced positive safety, tolerability and efficacy results from its recent analysis of the...
August 02, 2021
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Today, Satsuma announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for...
June 17, 2021
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Satsuma today announced positive PK, tolerability, and safety results from a Phase 1 trial of 5.2mg and to greater...
March 02, 2021
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) (Nasdaq: STSA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Satsuma today announced an update to the development plan for STS101 (DHE nasal powder). The updated development...
September 11, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Satsuma announces topline data from the Phase 3 EMERGE™ trial of STS101 for acute treatment of migraine. For more information,...
August 07, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS1011). Satsuma announced the initiation of patient enrollment in an ASCEND™ trial, a multi-center, open-label, 12-month study to...
June 01, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Satsuma reported completion of enrollment and randomization in its EMERGE pivotal Phase 3 efficacy trial of STS101, a multi-center,...
May 19, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Two Satsuma posters were selected for presentation on the 2020 American Academy of Neurology Annual Meeting Science Highlights...